DalsnaFinance › Analyst accuracy › UBS › AMGN target
Amgen (NASDAQ:AMGN) Rating Lowered to Hold at Wall Street Zen
Positive Sentiment: UBS upgraded Amgen to Buy and raised its price target to $470 from $430, implying further upside from the reported $414.87 share price.
A fact about what UBS published, as reported by MarketBeat, not a recommendation from Dalsna Finance; UBS is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.